US 12,076,360 B2
Herbal composition PHY906 and its use in chemotherapy
Shwu-Huey Liu, Madison, CT (US); Zaoli Jiang, Woodbridge, CT (US); and Yung-Chi Cheng, Woodbridge, CT (US)
Assigned to YALE UNIVERSITY, New Haven, CT (US)
Filed by YALE UNIVERSITY, New Haven, CT (US)
Filed on Aug. 21, 2023, as Appl. No. 18/236,081.
Application 18/236,081 is a continuation of application No. 17/714,530, filed on Apr. 6, 2022, granted, now 11,771,731.
Application 17/714,530 is a continuation of application No. 16/848,233, filed on Apr. 14, 2020, granted, now 11,324,793, issued on May 10, 2022.
Application 16/848,233 is a continuation of application No. 16/049,381, filed on Jul. 30, 2018, granted, now 10,646,530, issued on May 12, 2020.
Application 16/049,381 is a continuation of application No. 14/581,610, filed on Dec. 23, 2014, granted, now 10,058,580, issued on Aug. 28, 2018.
Application 14/581,610 is a continuation of application No. 13/648,597, filed on Oct. 10, 2012, abandoned.
Application 13/648,597 is a continuation in part of application No. 12/527,302, granted, now 8,309,141, issued on Nov. 13, 2012, previously published as PCT/US2008/053965, filed on Feb. 14, 2008.
Claims priority of provisional application 60/901,310, filed on Feb. 15, 2007.
Prior Publication US 2024/0075092 A1, Mar. 7, 2024
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 36/00 (2006.01); A61K 31/4412 (2006.01); A61K 31/7068 (2006.01); A61K 36/484 (2006.01); A61K 36/539 (2006.01); A61K 36/65 (2006.01); A61K 36/725 (2006.01)
CPC A61K 36/725 (2013.01) [A61K 31/4412 (2013.01); A61K 31/7068 (2013.01); A61K 36/484 (2013.01); A61K 36/539 (2013.01); A61K 36/65 (2013.01)] 20 Claims
 
1. A method of treating cancer in a mammal in need comprising administering to said mammal an anticancer composition in one or two parts comprising a therapeutically effective amount of sorafenib and an herbal preparation consisting essentially of a combination of Scutellaria baicalensis, Glycyrrhiza uralensis, Ziziphus jujuba and Paeonia lactiflora, wherein said composition is formulated in pharmaceutical dosage form in combination with a pharmaceutically acceptable carrier, additive and/or excipient thereof.